Вне эфира

Развивающийся сюжет · 1 репортаж

FDA panel review of seven unapproved peptides

Первый эфир Последний эфир

РазвиваетсяСледующая проверка : The committee’s recommendations on whether pharmacies may compound and dispense the seven peptides.

Текущее положение

The FDA Pharmacy Compounding Advisory Committee began its two-day review of seven unapproved peptides on July 23. FDA career scientists recommended against compounding all seven, citing a lack of human clinical data for three and inadequate data for the others; the committee’s recommendations have not yet been reported.

Ход сюжетаДень 1

1 материал11 изданий11 источников1 видео

  • Пока нет датированных событий
    1. Обновление 1Six Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record

    Сюжет на данный момент

    1. Обновление 1

      Six Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record

      A two-day meeting in Washington ended with a narrow recommendation to loosen compounding rules for unapproved compounds championed by influencers and RFK Jr. — over the objections of the agency's own staff.

      Остаётся открытым после этого материала

      • Whether the FDA will adopt the committee's recommendation in full or in part.
      • Which specific peptides failed to win a majority, given the gap between seven on the agenda and six (or four) endorsed.

    История

    1. Открыта1 репортаж

    Кто причастен

    Люди

    • Joe RoganAmerican broadcaster, comedian, and actor (born 1967)1 материал
    • Robert F. Kennedy Jr.26th United States Secretary of Health and Human Services since 20251 материал

    Места

    • ChinaChina1 материал
    • WashingtonWashington, DC, USA1 материал

    Все издания, которые мы прочитали по этому сюжету

    11 источников11 изданий1 видео